Russia Considers Ban on E-cigarette Additives: Industry Voices Concerns

Aug.09.2023
Russia Considers Ban on E-cigarette Additives: Industry Voices Concerns
Russia's Health Ministry is set to introduce a bill prohibiting certain additives in e-cigarettes, including nicotine salts and flavorings.

In a press conference, Artyom Metchelyov, Chairman of the Youth Policy Committee of the State Duma of Russia, announced that the Russian Ministry of Health will soon submit a bill to the Russian Cabinet for review, which aims to ban the use of additives in e-cigarettes.


This list of substances banned from increasing the appeal of nicotine-containing liquids includes:


Food additives, herbal flavoring agents, and their derivatives, including vanillin, cocoa and its derivatives, licorice, spices, and any natural flavorings are prohibited. Synthetic sugars and synthetic or natural sweeteners are also prohibited. Additionally, additives that enhance nicotine addiction, such as nicotine salts, ethanol, ammonium, and ammonia, are banned.


According to a report from the Russian newspaper "News Report" on August 8th, the Russian Union of Nicotine-Containing Product Industry (Союз предприятий индустрии никотиносодержащих изделий, abbreviated as СПИНИ) and the Professional Alliance of Participants in the Russian Market of Electronic Nicotine Systems (Профессиональный альянс участников русского рынка электронных никотиновых систем, abbreviated as ПАУРРЭНС) have sent a letter to Russian Finance Minister Anton Siluanov, requesting the removal of food flavorings and salt-based nicotine from the list of banned substances and additives.


This letter has received support from over 50 industry professionals and experts in the e-cigarette sector. Among them is Lev Grigoriev, Chairman of BABYLON, a leading e-cigarette compliant distributor in Russia, who also opposes the policy change.


Lev Grigoriev stated:


Flavorings are used in all e-cigarette liquids, many of which are not noticeable. Many flavorings are processed using technology and without them, the product would be unusable. In other words, it is illogical to completely ban all flavorings as there is no similar situation in the world.


The Ministry of Health recommends exclusively using liquid products containing propylene glycol and glycerol, much like suggesting a complete ban on all types of alcohol such as wine, liquor, brandy, and so on, and only utilizing pure ethanol.


The second recommendation concerns nicotine salts. What are nicotine salts? From a chemical standpoint, they are simply nicotine. So why does the Ministry of Health believe they can be addictive? Addiction is not caused by nicotine itself, but rather by its concentration.


The recommendation from the Ministry of Health is unlikely to solve the problem it claims to address - reducing the accessibility of nicotine products for minors and teenagers. Examples of similar bans include snus, a tobacco product in Sweden. Although snus is still available on the market, it is supplied illegally without the payment of taxes. This significantly impacts consumers who may be exposed to low-quality and unsafe products. Similarly, if the use of nicotine salts and flavorings is prohibited, the situation would likely be comparable.


What are the recommendations from industry experts regarding the market? It is not to completely ban all flavors, as e-cigarettes are composed of various substances.


Taking into account that minors make up approximately 11.2% of all e-cigarette consumers, we are actively striving to restrict accessibility to underage individuals. However, under the current circumstances, this measure would affect around 90% of adult users.


References:


[1] The business sector has requested not to ban the use of flavorings in vaping products. [2] Vape sellers are requesting not to ban flavorings.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As regulators pay closer attention to child safety in nicotine pouches, manufacturers face a practical challenge: how to strengthen child-resistant packaging without unnecessarily reworking products, production lines and regulatory submissions already in place. In a written interview with 2Firsts, Chemular detailed Safeguard’s external packaging approach, its customer-specific testing requirements and possible PMTA pathways. The model remains early-stage, but it offers a new way to think about an increasingly important regulatory and manufacturing issue.
Industry Insight
Sep.19
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
Philip Morris International’s IQOS has entered the Kantar BrandZ Top 100 Most Valuable Global Brands for the first time, ranking No. 74 with a brand value of $36.634 billion and becoming one of only three newcomers to the 2026 ranking. Kantar said the combined value of the Global Top 100 reached $13.1 trillion, up 22% year on year, while the threshold for entry rose to a record high. PMI says IQOS has more than 35 million users worldwide and surpassed $10 billion in annual net revenues within a decade of launch.
Sep.03
2Firsts On-Site | CTIHK Showcases Nicotine Pouches, Heated Tobacco and Chinese Cigars at InterTabac 2026
2Firsts On-Site | CTIHK Showcases Nicotine Pouches, Heated Tobacco and Chinese Cigars at InterTabac 2026
At InterTabac 2026 in Dortmund, China Tobacco International (HK) Company Limited (CTIHK) is exhibiting across two separate booths in Hall 5 and Hall 4. Products observed by 2Firsts include heated tobacco products, nicotine pouches, Chinese cigars and tobacco leaf. Nicotine pouch products on display include TOOP, Shuangxi and Ashima.
Market
Sep.16
Kantar Study Finds More Than 93% of Vape Products in Ukraine Fail Regulatory Requirements
Kantar Study Finds More Than 93% of Vape Products in Ukraine Fail Regulatory Requirements
According to Interfax-Ukraine, a study conducted by market research firm Kantar Ukraine at the request of major tobacco companies found that more than 93% of vape products in Ukraine did not fully comply with regulatory requirements. The research examined product categories, brand distribution and consumer purchasing channels, showing that pod systems and disposable vapes represent major segments of the market, while offline retail remains the dominant purchasing channel. The findings highlight ongoing compliance challenges in Ukraine’s vape market.
Aug.26
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
At InterTabac 2026, nicotine pouch growth was visible not only in brands but across equipment, raw materials and OEM manufacturing. 2Firsts interviewed AIRSCREAM commercial head Steve Moore on how many pouch factories Europe may ultimately need and where manufacturers can differentiate, from formulation and flavour to pouch materials, production consistency and customer service. The category continues to expand, but questions remain over future capacity, consolidation and the long-term structure of the supply chain.
Sep.18
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22